[IMCAS World 2026 Special] Shaping the Future: K-Medical Aesthetics Leading Innovation ㉓ | Interview with Seohyun Park, Director of External Relations, Primoris International
As exosomes emerge as a standalone category in the global medical aesthetics market, Korean bio-innovation companies with proven technology platforms are drawing growing attention. Primoris International, a global bio-innovation company with a broad ingredient portfolio spanning umbilical cord blood stem cell-derived exosomes, plant-derived exosomes, and plant PDRN, has expanded into more than 50 countries, with over 1.7 million clinical-use cases, according to the company. At IMCAS World Congress 2026 in Paris, Seohyun Park, Director of External Relations, unveiled the company's flagship products — P198 ExoHealer and ExoNature — alongside next-generation biostimulator coll:Re and the hybrid line Epiglow, while announcing plans to enter 25 additional markets this year. For a closer look at Primoris International's technology-driven global strategy and the latest trends shaping the exosome landscape, read the full interview via the link in our bio.
#MedicalAestheticNews #IMCAS2026 #PrimorisInternational #P198ExoHealer #P198ExoNature #Exosome #SkinBooster
★ Article Link: https://www.aestheticnews.co.kr/news/articleView.html?idxno=11280

Comments
Post a Comment